Disease-modifying treatments for multiple sclerosis - a review of approved medications
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Disease-modifying treatments for multiple sclerosis - a review of approved medications
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF NEUROLOGY
Volume 23, Issue -, Pages 18-27
Publisher
Wiley
Online
2015-11-13
DOI
10.1111/ene.12883
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Fertility, Pregnancy and Childbirth in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs
- (2015) Maria Pia Amato et al. CNS DRUGS
- PML in a Patient with Lymphocytopenia Treated with Dimethyl Fumarate
- (2015) Thorsten Rosenkranz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Freedom from disease activity in multiple sclerosis
- (2015) E. Havrdova et al. NEUROLOGY
- Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy
- (2014) Tatiana Plavina et al. ANNALS OF NEUROLOGY
- Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience
- (2014) Joachim Burman et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Assessment of cancer risk with β-interferon treatment for multiple sclerosis
- (2014) Elaine Kingwell et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy
- (2014) O. Tuohy et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2014) Aaron E Miller et al. LANCET NEUROLOGY
- Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2014) Christian Confavreux et al. LANCET NEUROLOGY
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Therapy-related acute leukaemia with mitoxantrone: Four years on, what is the risk and can it be limited?
- (2014) Richard Ellis et al. Multiple Sclerosis Journal
- Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study
- (2014) P. S. Sorensen et al. NEUROLOGY
- Multiple sclerosis: Prospects and promise
- (2013) Stephen L. Hauser et al. ANNALS OF NEUROLOGY
- Induction Therapy for Patients with Multiple Sclerosis: Why? When? How?
- (2013) Gilles Edan et al. CNS DRUGS
- Dimethyl Fumarate for Treatment of Multiple Sclerosis: Mechanism of Action, Effectiveness, and Side Effects
- (2013) Ralf A. Linker et al. Current Neurology and Neuroscience Reports
- Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial
- (2013) Patrick Vermersch et al. Multiple Sclerosis Journal
- Manufacturer's Response to Case Reports of PML
- (2013) Marianne T. Sweetser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Alemtuzumab: evidence for its potential in relapsing–remitting multiple sclerosis
- (2013) William Brown et al. Drug Design Development and Therapy
- Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta
- (2012) Robert A. Bermel et al. ANNALS OF NEUROLOGY
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- (2012) Jeffrey A Cohen et al. LANCET
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
- (2012) Alasdair J Coles et al. LANCET
- Scoring treatment response in patients with relapsing multiple sclerosis
- (2012) MP Sormani et al. Multiple Sclerosis Journal
- Hematopoietic Stem Cell Therapy for Multiple Sclerosis: Top 10 Lessons Learned
- (2012) Harold L. Atkins et al. Neurotherapeutics
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- (2012) Ralf Gold et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
- (2012) Gary Bloomgren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Teriflunomide for oral therapy in multiple sclerosis
- (2012) Athina Papadopoulou et al. Expert Review of Clinical Pharmacology
- Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial
- (2011) G. Edan et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial
- (2011) Giancarlo Comi et al. LANCET NEUROLOGY
- The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-1a: analysis of data from clinical trial and post-marketing surveillance settings
- (2011) Magnhild Sandberg-Wollheim et al. Multiple Sclerosis Journal
- Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone
- (2011) V. Martinelli et al. NEUROLOGY
- Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
- (2011) Paul O'Connor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases
- (2010) David B Clifford et al. LANCET NEUROLOGY
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
- (2010) Jeffrey A. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
- (2009) G Comi et al. LANCET
- 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
- (2009) Paul O'Connor et al. LANCET NEUROLOGY
- Mitoxantrone: benefits and risks in multiple sclerosis patients
- (2009) V. Martinelli et al. NEUROLOGICAL SCIENCES
- Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
- (2008) Daniel D Mikol et al. LANCET NEUROLOGY
- Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients
- (2008) J Río et al. Multiple Sclerosis Journal
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
- (2008) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now